ReviewEuropean journal of nuclear medicine and molecular imaging2020
Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development.
Review in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Synthesis and Preclinical Evaluation of [ACS omega · 2026Article
- Article
- Neuroimaging in advanced Parkinson's disease: insights into pathophysiology, biomarkers, and personalized therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Development of [Nature communications · 2025Article
- Human subject study of a transmission-aided attenuation correction for precision PET neuroimaging.EJNMMI physics · 2025Article
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Synthesis and in vitro evaluation of spirobenzovesamicols as potentialEJNMMI radiopharmacy and chemistry · 2025Article
- Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- DOCK-PET: database of CNS kinetic parameters in the healthy human brain for existing PET tracers.Annals of nuclear medicine · 2024Article
- Advancing Parkinson's Disease Diagnostics: The Potential of Arylpyrazolethiazole Derivatives for Imaging α-Synuclein Aggregates.ACS omega · 2024Article
- Schizophrenia: from neurochemistry to circuits, symptoms and treatments.Nature reviews. Neurology · 2024Review
- Biomarker Methodologies: A NIMH Perspective.Advances in neurobiology · 2024Review
- The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment.Frontiers in medicine · 2024Review
- Site-specifically radiolabeled nanobodies for imaging blood-brain barrier penetration and targeting in the brain.Journal of labelled compounds & radiopharmaceuticals · 2023Review
- Peering into the Brain's Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders.Biomolecules · 2023Article
- Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Redox and Immune Signaling in Schizophrenia: New Therapeutic Potential.The international journal of neuropsychopharmacology · 2023Review
- The synaptic hypothesis of schizophrenia version III: a master mechanism.Molecular psychiatry · 2023Review
- Positron Emission Tomography of Neuroimmune Responses in Humans: Insights and Intricacies.Seminars in nuclear medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeA limit on developing new treatments for a number of central nervous system (CNS) disorders has been the inadequate understanding of the in vivo pathophysiology underlying neurological and psychiatric disorders and the lack of in vivo tools to determine brain penetrance, target engagement, and relevant molecular activity of novel drugs. Molecular neuroimaging provides the tools to address this. This article aims to provide a state-of-the-art review of new PET tracers for CNS targets, focusing on developments in the last 5 years for targets recently available for in-human imaging.
methodsWe provide an overview of the criteria used to evaluate PET tracers. We then used the National Institute of Mental Health Research Priorities list to identify the key CNS targets. We conducted a PubMed search (search period 1st of January 2013 to 31st of December 2018), which yielded 40 new PET tracers across 16 CNS targets which met our selectivity criteria. For each tracer, we summarised the evidence of its properties and potential for use in studies of CNS pathophysiology and drug evaluation, including its target selectivity and affinity, inter and intra-subject variability, and pharmacokinetic parameters. We also consider its potential limitations and missing characterisation data, but not specific applications in drug development. Where multiple tracers were present for a target, we provide a comparison of their properties. RESULTS AND
conclusionsOur review shows that multiple new tracers have been developed for proteinopathy targets, particularly tau, as well as the purinoceptor P2X7, phosphodiesterase enzyme PDE10A, and synaptic vesicle glycoprotein 2A (SV2A), amongst others. Some of the most promising of these include
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.